First-in-class
drugs through

targeted stabilization

of protein complexes

First-in-class drugs through

targeted stabilization

of protein complexes

Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins.

APPROACH

Driven by the need for new therapeutic options for cancer patients, our team is harnessing our deep scientific expertise and drug discovery know-how to create first in class protein-protein interaction stabilizer drugs as novel targeted cancer treatments.

Ambagon’s approach selectively augments the endogenous tumor suppression activity of 14-3-3 proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conventional approaches. Ambagon’s platform approach will also open opportunities to address other major unmet clinical needs.

Ambagon has sites in San Francisco, CA, USA and Eindhoven, Netherlands

TEAM

Ambagon was inspired by the world-class research in the laboratories of our co-founders.

 

COFOUNDERS:

Michelle Arkin, Ph.D.

Michelle Arkin, Ph.D.

Co-Founder, Director
Luc Brunsveld, Ph.D.

Luc Brunsveld, Ph.D.

Co-Founder, Scientific Advisor
Christian Ottmann, Ph.D.

Christian Ottmann, Ph.D.

Co-Founder, Chief Technology Officer

LEADERSHIP:

Nancy Pryer, Ph.D.

Nancy Pryer, Ph.D.

Chief Scientific Officer
Adam Rosenberg

Adam Rosenberg

Executive Chair
Bryan Miller

Bryan Miller

Chief Financial Officer

NEWS

Ambagon’s novel approach was recognized with several awards during early company formation.

Ambagon was awarded two Golden Tickets, which provide one year’s priority admission or renewal to MBC BioLabs’ state-of-the-art laboratory.  Ambagon was awarded a Golden Ticket each from AbbVie Ventures and Astellas Venture Management in 2019.  Read the announcement of the Astellas Golden Ticket here:


https://mbcbiolabs.com/mbc-biolabs-news/announcing-winners-of-the-2019-astellas-golden-ticket/

Ambagon was also the winner of the Dutch Venture Challenge and was awarded a prize of €25,000.  Read about Ambagon winning the Dutch Venture Challenge here: 


https://www.health-holland.com/news/2019/06/the-winner-of-the-venture-challenge-is-ambagonand

CONTACT

SAN FRANCISCO

953 Indiana Street

San Francisco, CA 94107

EINDHOVEN

Catalyst 1.21, De Lismortel

31  5612 AR, Eindhoven, NL

© 2020 Ambagon Therapeutics, Inc.. All Rights Reserved.